GlaxoSmithKline: Vomiting trials

The registry lists 28 Vomiting studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 14Phase 2 6Phase 3 7No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic ChemotherapyCompletedNCT01500226Phase 3Results posted
• Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic ChemotherapyCompletedNCT01500213Phase 3Results posted
• Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic ChemotherapyCompletedNCT01499849Phase 3Results posted
• A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.CompletedNCT00601172Phase 3Results posted
• An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy SubjectsCompletedNCT02434861Phase 1
• A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy VolunteersCompletedNCT02382666Phase 1
• An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous RolapitantCompletedNCT02285647Phase 1
• To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult SubjectsCompletedNCT01449188Phase 1
• CV Events in Emetogenic ChemotherapyCompletedNCT01366599
• A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic ChemotherapyWithdrawnNCT00891761Phase 3
• Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female PatientsCompletedNCT00600990Phase 2
• The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in SubjectsCompletedNCT00511823Phase 1
• A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy AdultsCompletedNCT00460707Phase 1
• The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With CancerCompletedNCT00440128Phase 1
• A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy AdultsCompletedNCT00437229Phase 1
• A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic ChemotherapyCompletedNCT00431236Phase 3
• Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy InfantsCompletedNCT00429481Phase 2
• A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).CompletedNCT00405080Phase 1
• Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]CompletedNCT00404378Phase 1
• A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human VolunteersCompletedNCT00404274Phase 1
• Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And VomitingCompletedNCT00366834Phase 3
• Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic ImpairmentCompletedNCT00359177Phase 1
• Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal ImpairmentCompletedNCT00358813Phase 1
• Cyclophosphamide Drug Interaction Study In Cancer PatientsTerminatedNCT00334646Phase 1
• Post-Operative Nausea And Vomiting Study In Female PatientsCompletedNCT00274690Phase 2
• Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based ChemotherapyCompletedNCT00169572Phase 2
• A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And VomitingCompletedNCT00108095Phase 2
• Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic ChemotherapyCompletedNCT00104403Phase 2